Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.

Abstract excerpt

Human pancreatic cancer has a very poor prognosis with an overall five-year survival rate of less than 5% and an average median survival time of six months. This is largely due to metastatic disease, which is already present in the majority of patients when diagnosed. Although our understanding of the molecular events underlying multi-step carcinogenesis in pancreatic cancer has steadily increased, translation...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Cell Transformation, Neoplastic
• Disease Management
• Genomic Instability
• Genomics